CervoMed, dementia

CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial, sending the U.S. drug developer shares down 77% in early trading.
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study.
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility,
CervoMed: Neflamapimod Phase 2b Trial In Dementia With Lewy Bodies Patients Fails To Meet Targets
CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia
FDA grants orphan drug designation to CervoMed’s dementia drug
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational small molecule drug, Neflamapimod, for the treatment of frontotemporal dementia. The FDA’s decision is on based promising results from the company’s Phase 1 and 2 studies.
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, neflamapimod,
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...
Hosted on MSN14d
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug
The US Food and Drug Administration (FDA) has granted orphan drug designation to CervoMed’s lead investigational therapy ...
devdiscourse2d
Drug Breakthroughs and Setbacks: A Week in Pharmaceutical Innovations
Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...